CXA-201 + Levofloxacin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Urinary Tract Infection
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Trial Timeline
Jun 20, 2011 → Sep 4, 2013
NCT ID
NCT01345929About CXA-201 + Levofloxacin
CXA-201 + Levofloxacin is a phase 3 stage product being developed by Merck for Complicated Urinary Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01345929. Target conditions include Complicated Urinary Tract Infection, Pyelonephritis.
What happened to similar drugs?
4 of 20 similar drugs in Complicated Urinary Tract Infection were approved
Approved (4) Terminated (3) Active (15)
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01345929 | Phase 3 | Completed |
Competing Products
20 competing products in Complicated Urinary Tract Infection